Description

ACE-031 1mg (95% Untagged Premium) – ActRIIB Research Protein

ACE-031 1mg (95% Untagged Premium) is a research product associated with scientific investigations into myostatin signalling, activin receptor biology and the regulation of skeletal muscle mass.

ACE-031 is the name of an investigational recombinant fusion protein developed to interact with selected members of the transforming growth factor-beta (TGF-beta) superfamily. The clinically investigated molecule combines the extracellular ligand-binding domain of activin receptor type IIB (ActRIIB) with a human immunoglobulin G1 Fc region.

The ACE-031 research programme explored whether modifying myostatin and related signalling pathways could influence muscle-related outcomes in experimental models and individuals with Duchenne muscular dystrophy.

For this ACE-031 1mg listing, the exact molecular identity, untagged designation and stated purity must be supported by product-specific analytical documentation. Commercially advertised ACE-031 materials are not necessarily equivalent to the original clinical research molecule.

What Is ACE-031?

ACE-031 is an investigational protein originally developed as a soluble activin receptor type IIB fusion construct.

The ActRIIB component can bind selected extracellular signalling proteins, while the Fc region forms part of the engineered fusion protein.

By binding certain ligands outside the cell, ACE-031 was designed to interfere with signalling pathways involved in muscle growth regulation.

These pathways are scientifically important, but ACE-031 is not an approved medicine for muscle development, weight management or muscular dystrophy.

ACE-031 1mg Product Specifications

• Product Name: ACE-031 1mg (95% Untagged Premium)
• Research Compound: ACE-031
• Related Name: ActRIIB-Fc
• Labelled Quantity: 1mg
• Advertised Purity: 95% – requires batch-specific verification
• Advertised Format: Untagged – requires manufacturer confirmation
• Original Investigational Molecule: Recombinant ActRIIB-IgG1 Fc fusion protein
• Research Category: Myostatin and activin receptor signalling
• Research Focus: Skeletal muscle regulation, ligand binding and TGF-beta superfamily signalling
• Exact Molecular Identity: Requires product-specific analytical confirmation
• Molecular Weight: Depends on the verified molecular construct and modification state
• Storage: Follow verified manufacturer instructions

Understanding the ACE-031 Molecular Structure

The original ACE-031 investigational molecule is a recombinant fusion protein rather than a short synthetic peptide.

It contains an extracellular portion of the activin receptor type IIB joined to an IgG1 Fc domain.

This engineered structure was designed to interact with circulating ligands associated with muscle growth regulation.

Protein identity is influenced by its amino acid sequence, folding, glycosylation, molecular assembly and manufacturing process.

For this reason, a short peptide marketed under the ACE-031 name should not be assumed to have the same structure or biological activity as the original fusion protein.

How ACE-031 Was Designed to Work

ACE-031 was developed as a soluble ligand-binding protein, sometimes described as a decoy receptor or ligand trap.

Its purpose was to bind selected extracellular proteins that would otherwise interact with cell-surface receptors.

Among the relevant signalling molecules are myostatin and other members of the TGF-beta superfamily.

Myostatin is involved in the biological regulation of skeletal muscle mass. Interfering with its signalling has therefore been investigated as a potential strategy in muscle-related research.

However, the activin receptor pathway has functions beyond skeletal muscle. Broad ligand binding can affect additional biological systems, making selectivity and safety important research considerations.

Scientific Research Into ACE-031

1. Myostatin Signalling Research

Myostatin, also known as growth differentiation factor 8 (GDF-8), is a signalling protein involved in limiting skeletal muscle growth.

ACE-031 was designed to bind myostatin and related ligands, reducing their availability to interact with endogenous receptors.

Research into this mechanism has contributed to scientific understanding of muscle growth regulation and the challenges associated with broad ligand inhibition.

These findings do not establish that a commercially supplied ACE-031-labelled research product has equivalent activity.

2. Activin Receptor Type IIB Research

Activin receptor type IIB participates in signalling involving multiple TGF-beta superfamily ligands.

The extracellular portion of this receptor was incorporated into the original ACE-031 fusion protein to create a soluble ligand-binding construct.

Investigations of ActRIIB signalling help researchers understand the relationship between growth factor pathways, muscle physiology and other tissue responses.

Because the receptor interacts with several ligands, modifying this pathway may produce effects outside the intended muscle-related research target.

3. Duchenne Muscular Dystrophy Clinical Research

ACE-031 reached clinical investigation in boys with Duchenne muscular dystrophy, a genetic condition associated with progressive muscle weakness.

A randomised, placebo-controlled clinical study evaluated safety and measured exploratory outcomes involving lean body mass, bone mineral density and physical function.

The study reported trends in some muscle-related measurements, but the findings were limited and did not establish a clinically validated treatment benefit.

Importantly, the trial was stopped early following safety concerns, including epistaxis (nosebleeds) and telangiectasias (dilated superficial blood vessels).

ACE-031 did not progress to an approved treatment for Duchenne muscular dystrophy.

4. Lean Body Mass Research

Clinical investigations of the original ACE-031 fusion protein included measurements of lean body mass.

Researchers examined whether changes in myostatin-related signalling were associated with measurable changes in body composition.

Some studies reported changes or trends in lean mass, but these results must be interpreted alongside study limitations and the safety concerns that ended development.

They should not be presented as proof that ACE-031 safely increases muscle mass in healthy people.

5. Bone Biology Research

ACE-031 studies also included measurements related to bone mineral density.

These investigations reflected the broader biological roles of activin receptor-associated signalling pathways.

Exploratory findings suggested possible changes in certain bone-related measurements, but they were not sufficient to establish therapeutic benefits.

ACE-031 is not an approved treatment for osteoporosis or other bone disorders.

6. Ligand Selectivity and Vascular Safety

An important lesson from the ACE-031 development programme concerns the potential consequences of interacting with multiple signalling ligands.

Myostatin is not the only protein associated with activin receptor signalling. Related pathways contribute to vascular and other physiological functions.

During clinical investigation, adverse events involving bleeding and visible blood vessel changes raised safety concerns.

These findings demonstrate why research into ligand selectivity is essential when evaluating experimental growth factor pathway inhibitors.

What Does 95% Untagged Premium Mean?

The phrase 95% Untagged Premium appears in the commercial name of this product.

A stated purity of 95% should be supported by batch-specific analytical testing. The analytical method must be appropriate for the actual molecular material.

The term untagged generally refers to a recombinant protein or peptide produced without an additional engineered affinity or detection tag.

However, the meaning of untagged must be established by the manufacturer. It should not be confused with the Fc region, which is an integral component of the original ACE-031 fusion protein.

The word premium is a commercial descriptor rather than a recognised scientific quality standard.

None of these terms independently verifies biological activity, sterility, correct folding or equivalence to the original investigational ACE-031 molecule.

ACE-031 vs Conventional Myostatin Inhibitors

ACE-031 is associated with the broader field of myostatin inhibition, but different investigational compounds use different molecular strategies.

• ACE-031: An investigational ActRIIB-Fc fusion protein designed to bind multiple ligands.
• Myostatin-Neutralising Antibodies: Investigational antibodies designed to bind myostatin more directly.
• Other Activin Receptor Constructs: Engineered molecules that may differ in ligand selectivity, molecular structure and biological properties.

Results obtained with one myostatin-related compound cannot automatically be transferred to another.

ACE-031 and Weight Management Research

ACE-031 is sometimes discussed in relation to body composition because clinical studies measured lean and fat mass.

However, ACE-031 is not an established weight-loss medicine.

The available evidence does not support claims that it safely reduces body fat, improves metabolism or provides a clinically validated approach to weight management.

Its research history is primarily associated with muscle-related signalling and Duchenne muscular dystrophy.

Understanding the ACE-031 1mg Label

The 1mg designation describes the labelled quantity of research material.

It does not represent a recommended human dose or establish the material’s molecular identity, activity, purity or suitability for administration.

For recombinant proteins, the stated mass alone provides limited information about biological activity.

Researchers should verify whether the material is the original ActRIIB-Fc fusion protein, a different recombinant construct or a shorter peptide marketed under the same name.

Research Quality and Product Documentation

Important considerations when evaluating ACE-031-labelled research material include:

• Full molecular identity and amino acid sequence
• Confirmation of whether the material is an ActRIIB-Fc fusion protein or a shorter peptide
• Verification of the advertised untagged designation
• Batch-specific certificate of analysis
• Purity testing appropriate to the molecular material
• Identity testing using suitable analytical methods
• Evidence of protein integrity and aggregation status, where relevant
• Manufacturer and batch traceability
• Verified labelled quantity
• Product-specific storage and stability documentation
• Clearly stated research-use restrictions

These records are especially important when a commercial product name is shared by materials that may differ substantially in chemical structure.

Storage and Handling Considerations

ACE-031 research material should be stored according to verified manufacturer instructions.

Appropriate storage conditions depend on the exact molecular construct, formulation, physical state, packaging and available stability data.

Large recombinant proteins can have handling requirements that differ from those of short synthetic peptides.

Generic peptide storage guidance should not replace the technical documentation for the actual material supplied.

ACE-031 Safety and Research Limitations

ACE-031 is an investigational compound whose clinical development was discontinued following safety concerns.

Published research reported adverse events including nosebleeds and telangiectasias during clinical investigation.

The available evidence does not establish ACE-031 as a safe or effective treatment for muscle growth, Duchenne muscular dystrophy or weight management.

Commercial research materials bearing the ACE-031 name should not be assumed equivalent to the clinically investigated fusion protein.

ACE-031 is not an established FDA-, EMA- or MHRA-approved medicine for human therapeutic use.

This information is intended for scientific and educational purposes only. It does not provide medical advice, human dosing recommendations or administration instructions.

Frequently Asked Questions About ACE-031 1mg

What is ACE-031?

ACE-031 is an investigational ActRIIB-Fc fusion protein developed to interact with myostatin and related signalling ligands.

Is ACE-031 a peptide or a protein?

The original ACE-031 molecule studied clinically is a recombinant fusion protein rather than a conventional short synthetic peptide.

What is ACE-031 researched for?

ACE-031 has been investigated in research involving myostatin signalling, skeletal muscle regulation and Duchenne muscular dystrophy.

What does 95% purity mean?

It is an advertised analytical purity specification that must be verified using appropriate batch-specific testing.

What does untagged mean?

Untagged generally indicates the absence of an additional engineered purification or detection tag. The exact designation must be confirmed from manufacturer documentation.

Does ACE-031 increase muscle mass?

Some clinical investigations reported changes or trends in lean body mass, but the development programme was discontinued because of safety concerns. ACE-031 is not an approved muscle-building treatment.

Why was ACE-031 development stopped?

Clinical development was stopped following safety concerns involving nosebleeds and telangiectasias.

Is ACE-031 approved for medical use?

No. ACE-031 is not an established approved medicine for human therapeutic use.

Is ACE-031 used for weight loss?

ACE-031 is not an established weight-loss medicine, and its safety and effectiveness for weight management have not been demonstrated.

What does ACE-031 1mg mean?

The 1mg designation refers to the labelled quantity of research material, not a recommended dose.

ACE-031 1mg (95% Untagged Premium) – Product Summary

ACE-031 1mg (95% Untagged Premium) is a research product associated with investigations into activin receptor signalling, myostatin biology and skeletal muscle regulation.

The original ACE-031 molecule was a recombinant ActRIIB-Fc fusion protein investigated in clinical studies of Duchenne muscular dystrophy. Its development was discontinued following safety concerns.

For research material sold under this name, verification of the exact molecular identity is essential. Researchers should confirm whether the supplied compound matches the original fusion protein or represents a different peptide construct.

Product purity, analytical identity, batch documentation, formulation and storage requirements should be established before selecting the material for laboratory investigation.